Loading organizations...
§ Private Profile · Burlington, MA, USA
Gene coding company developing curative therapies for inherited disorders.
SalioGen Therapeutics has raised $135.0M across 2 funding rounds.
SalioGen Therapeutics has raised $135.0M in total across 2 funding rounds.
SalioGen Therapeutics has raised $135.0M across 2 funding rounds. Most recently, it raised $115.0M Series B in January 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 5, 2022 | $115M Series B | Epiq Capital Group, Craig Gordon | Martin Mense, D1 Capital Partners, Fidelity Management & Research Company, PBM Capital, RD Fund, SymBiosis, T. Rowe Price Associates | Announced |
| Mar 1, 2021 | $20M Series A | Sean Stalfort | — | Announced |
SalioGen Therapeutics has raised $135.0M in total across 2 funding rounds.
SalioGen Therapeutics's investors include EPIQ Capital Group, Craig Gordon, Martin Mense, D1 Capital Partners, Fidelity Management & Research Company, PBM Capital, RD Fund, SymBiosis, T. Rowe Price Associates, Sean Stalfort.